The Oncologist: The relationship between HER2 gene changes and microsatellite instability (MSI-H) in colorectal adenocarcinoma

Colorectal cancer (CRC) ranks fourth in incidence and fifth in mortality among malignant tumors in China.

Colorectal cancer (CRC) ranks fourth in incidence and fifth in mortality among malignant tumors in China.

Include patients who have undergone next-generation sequencing (NGS) from 2017.

Include patients who have undergone next-generation sequencing (NGS) from 2017.

Patient clinical characteristics

Patient clinical characteristics

Mutation type

Mutation type

The median progression-free period (DFS) of patients with HER2 genetic changes was 17.

The median progression-free period (DFS) of patients with HER2 genetic changes was 17.

DFS analysis

DFS analysis

Twenty-five patients with MSI-H received PD-1 monoclonal antibody treatment, of which 9 had HER2 mutations and 16 had no HER2 changes.

Twenty-five patients with MSI-H received PD-1 monoclonal antibody treatment, of which 9 had HER2 mutations and 16 had no HER2 changes.

Anti-PD1 treatment for DFS

 Anti-PD1 treatment for DFS

In summary, the proportion of MSI-H found in HER2 mutation cases is higher, but MSI-H is not found in HER2 amplified cases.

In summary, the proportion of MSI-H found in HER2 mutation cases is higher, but MSI-H is not found in HER2 amplified cases.

Original source:

ncbi.

ncbi.
nlm.
nih.
gov/?term=Qiu+MZ&cauthor_id=33844372">Miao-Zhen Qiu ,  ncbi.
nlm.
nih.
gov/?term=He+CY&cauthor_id=33844372">Cai-Yun He  ,  ncbi.
nlm.
nih.
gov/?term=Yang+XH&cauthor_id=33844372">Xin-Hua Yang  ,et al.
Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma.
Oncologist.
2021 Apr 12.
doi: 10.
1002/onco.
13786.
Online ahead of print.
ncbi.
nlm.
nih.
gov/?term=Qiu+MZ&cauthor_id=33844372">Miao -Zhen Qiu ncbi.
nlm.
nih.
gov/?term=He+CY&cauthor_id=33844372">Cai-Yun He ncbi.
nlm.
nih.
gov/?term=Yang+XH&cauthor_id=33844372">Xin-Hua Yang leaves a message here